Therapeutic | Moxetumomab |
Target | CD22 |
Heavy Chain | EVQLVESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKCLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGTHWGVLFAYWGQGTLVTVSA |
Light Chain | DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGCGTKLEI |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Fv Fusion |
Isotype | na |
Highest Clinical Trial (August '23) | Approved |
Estimated Status (August '23) | NFD |
Recorded Developmental Technology | CAT Phage Display |
INN Year Proposed | 2009 |
INN Year Recommended | 2010 |
Companies Involved | National Cancer Institute %28USA%29%3BAstraZeneca%3BM. D. Anderson Cancer Center%3BMedImmune%3BNational Cancer Institute %28USA%29 |
Conditions Approved | Hairy cell leukaemia |
Conditions Active | na |
Conditions Discontinued | Chronic lymphocytic leukaemia%3BNon-Hodgkin%27s lymphoma%3BPrecursor B-cell lymphoblastic leukaemia-lymphoma%3BPrecursor cell lymphoblastic leukaemia-lymphoma |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]